Table 5.
Blastocysts recorded at different time points after microinjection of CDC5L antibody into MII oocytes followed by parthenogenetic activation
Control, without microinjection; NC, microinjected negative control; siCDC5L, microinjected cdc5l siRNAs. a-b and A-B indicate significant differences at p < 0.05 and p < 0.01 levels within the same subcolumns, respectively.
| Group | Total embryos | Total No. balstocyst | No. blastocoelic balstocyst | No. expanded blastocyst | No. hatched blastocyst | |
|---|---|---|---|---|---|---|
| % ± S.D. | ||||||
| Day 5 | Control | 144 | 41 (29.6 ± 10.6%)AB | 16 (11.4 ± 3.7%) | 25 (18.2 ± 9.2%)AB | 0 |
| IgG | 147 | 50 (34.3 ± 4.8%)A | 13 (8.8 ± 3.0%) | 37 (25.5 ± 6.8%)A | 0 | |
| Anti-CDC5L | 137 | 23 (16.7 ± 4.3%)B | 8 (5.8 ± 1.0%) | 15 (10.9 ± 4.3%)B | 0 | |
| Day 6 | Control | 144 | 65 (45.4 ± 2.3%)A | 15 (10.4 ± 1.5%) | 48 (33.7 ± 4.3%)A | 2 (1.3 ± 1.1%) |
| IgG | 147 | 75 (50.8 ± 2.8%)A | 16 (10.6 ± 5.6%) | 55 (37.5 ± 2.7%)A | 5 (3.4 ± 2.4%) | |
| Anti-CDC5L | 137 | 36 (27.2 ± 5.3%)B | 10 (7.4 ± 3.8%) | 26 (19.1 ± 8.7%)B | 0 | |
| Day 7 | Control | 144 | 68 (47.4 ± 2.8%)A | 14 (9.6 ± 2.2%) | 49 (34.2 ± 1.6%)A | 5 (3.6 ± 1.7%) |
| IgG | 147 | 75 (50.8 ± 2.8%)A | 10 (6.6 ± 4.1%) | 58 (39.6 ± 2.3%)A | 7 (4.7 ± 2.1%) | |
| Anti-CDC5L | 137 | 38 (28.0 ± 5.5%)B | 10 (7.3 ± 2.5%) | 27 (20.0 ± 9.4%)B | 1 (0.7 ± 1.2%) | |